>I somehow doubt that Dew ever gave more than a few seconds consideration to such procedures for himself…<
Actually, beachgal, I’ve sampled a few of these treatments—including Botox and Restylane—to have a better idea of the investment appeal of the companies that purvey them. And I talk to “injectors” – the silly-sounding term that the drug companies use to refer to the people who administer the treatments.
Artefill/Artecoll is considered by many injectors to be a loser for the reasons I cited in an earlier post. Many doctors won’t even consider it because of the risk, however modest, of permanent disfigurement.
Moreover, the newer hyaluronic-acid fillers such as Restylane last long enough (6-12 months) that duration is not nearly as big an issue for consumers as it was with the shorter-acting collagen fillers such as the ones sold by IMDC and MNT.
By the way, a little known aspect of Botox is that the potency varies considerably from batch to batch, and this variation is inherent in AGN’s archaic botulinum technology. Regards, Dew
Market Data 
Markets 
AI
